Worth reading
35Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateInvestment amount by sectorField NIB101 development costs / Amount 530 million yen, Field NIB103 development costs / Amount 1,110 million yen, Field Costs of preclinical trials for NIB104 and subsequent programs / Amount 150 million yen, Field Research expenses related to the creation of new pipelines / Amount 130 million yen, Field Research expenses related to new platform technologies / Amount 90 million yen, Field Working capital / Amount 447 million yen
Key initiatives
01Advance development of NIB103, the company’s proprietary drug discovery pipeline, as the priority pipeline
02Accelerate preparations for the start of an investigator-initiated clinical trial for NIB104, the subsequent pipeline
03Strengthen research and development of novel technologies and therapeutic modalities to create next-generation gene and cell therapies
04Accelerate business development based on Swift PRIME CAR-T cells produced using an accelerated manufacturing process and in vivo CAR-T technology
05Maximize the number of concurrent pipelines
06Expand the Addressable Patient Population by using targets held by other companies
07Pursue stable management by securing upfront payments and milestones from joint research pipelines at an early stage
08In partnered pipeline businesses, the company’s costs can be kept to a minimum
09Consider potential license-out transactions in parallel
Plan assumptionsCAR-T market growth rate: 23.35% CAGR (2024–2033), Pipeline development in Japan assumes use of the expedited approval system for regenerative medical products, The timing of applications and approvals for NIB103 and NIB104, among other matters, is not definitive
Size of the Target MarketMarket Size Not disclosed / Growth rate 23.35% CAGR (2024–2033) / Source Vision Research Reports（https://www.visionresearchreports.com/car-t-cell-therapy-market/40008）
Risks identified by the company
Forward-looking statements are subject to various risks and uncertainties
Actual results may differ materially from the forecasts presented in the forward-looking statements
Actual development progress may differ materially from the outlook
The timing of applications and approvals, among other matters, is not definitive
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | NIB103: 2024–2031; NIB104: 2025–2033 (outlook for each pipeline) |
| Progress against the plan | Annual update |
| Investment amount by sector | Field NIB101 development costs / Amount 530 million yen, Field NIB103 development costs / Amount 1,110 million yen, Field Costs of preclinical trials for NIB104 and subsequent programs / Amount 150 million yen, Field Research expenses related to the creation of new pipelines / Amount 130 million yen, Field Research expenses related to new platform technologies / Amount 90 million yen, Field Working capital / Amount 447 million yen |
| Plan assumptions | CAR-T market growth rate: 23.35% CAGR (2024–2033), Pipeline development in Japan assumes use of the expedited approval system for regenerative medical products, The timing of applications and approvals for NIB103 and NIB104, among other matters, is not definitive |
| Key initiatives | Advance development of NIB103, the company’s proprietary drug discovery pipeline, as the priority pipeline, Accelerate preparations for the start of an investigator-initiated clinical trial for NIB104, the subsequent pipeline, Strengthen research and development of novel technologies and therapeutic modalities to create next-generation gene and cell therapies, Accelerate business development based on Swift PRIME CAR-T cells produced using an accelerated manufacturing process and in vivo CAR-T technology, Maximize the number of concurrent pipelines, Expand the Addressable Patient Population by using targets held by other companies, Pursue stable management by securing upfront payments and milestones from joint research pipelines at an early stage, In partnered pipeline businesses, the company’s costs can be kept to a minimum, Consider potential license-out transactions in parallel |
| Size of the Target Market | Market Size Not disclosed / Growth rate 23.35% CAGR (2024–2033) / Source Vision Research Reports（https://www.visionresearchreports.com/car-t-cell-therapy-market/40008） |
| Risks identified | Forward-looking statements are subject to various risks and uncertainties, Actual results may differ materially from the forecasts presented in the forward-looking statements, Actual development progress may differ materially from the outlook, The timing of applications and approvals, among other matters, is not definitive |
| Publication date | 2026.3 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetNon-financial targetsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason for updating or reviewing the business plan was provided.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.